{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-24-000036","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2024-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.064327+00:00","generated_at":"2026-05-31T22:47:42.869592+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexicon appoints Michael Exton as CEO effective July 8, 2024; Jeffrey Wade promoted to President and COO","bullets":["New CEO Michael Exton, Ph.D., former Novartis cardiometabolism head, to lead Lexicon starting July 8, 2024.","Exton receives $636k base salary, 70% bonus target, and stock option for 1,675,000 shares vesting over 4 years.","Jeffrey Wade promoted from President/CFO to President/COO; base salary increased to $585k, bonus target to 60%.","Wade granted stock option for 307,000 shares vesting over 4 years; also remains principal financial officer.","Severance for Exton: 12 months salary on termination w/o cause; additional one-time bonus target on change of control."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-24-000036","json":"https://secwatch.observer/filing/0001062822-24-000036.json","markdown":"https://secwatch.observer/filing/0001062822-24-000036.md","text":"https://secwatch.observer/filing/0001062822-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000036/0001062822-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000036/lxrx-20240703.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:47:42.869592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad4437e652","claim":"Michael Exton was appointed as Chief Executive Officer at LEXICON PHARMACEUTICALS, INC..","evidence_excerpt":"Michael Exton, Ph.D. was appointed as our chief executive officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000036/0001062822-24-000036-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b4b5ccc3f0","claim":"Michael Exton was elected as Director at LEXICON PHARMACEUTICALS, INC..","evidence_excerpt":"elected to serve as a member of our board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000036/0001062822-24-000036-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}